|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: STK16 |
Gene summary for STK16 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | STK16 | Gene ID | 8576 |
| Gene name | serine/threonine kinase 16 | |
| Gene Alias | KRCT | |
| Cytomap | 2q35 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A024R440 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8576 | STK16 | P23T-E | Human | Esophagus | ESCC | 1.53e-17 | 4.01e-01 | 0.108 |
| 8576 | STK16 | P24T-E | Human | Esophagus | ESCC | 8.39e-17 | 4.33e-01 | 0.1287 |
| 8576 | STK16 | P26T-E | Human | Esophagus | ESCC | 2.70e-25 | 3.57e-01 | 0.1276 |
| 8576 | STK16 | P27T-E | Human | Esophagus | ESCC | 2.77e-23 | 4.08e-01 | 0.1055 |
| 8576 | STK16 | P28T-E | Human | Esophagus | ESCC | 8.96e-16 | 3.00e-01 | 0.1149 |
| 8576 | STK16 | P30T-E | Human | Esophagus | ESCC | 1.07e-22 | 6.98e-01 | 0.137 |
| 8576 | STK16 | P31T-E | Human | Esophagus | ESCC | 4.38e-21 | 3.29e-01 | 0.1251 |
| 8576 | STK16 | P32T-E | Human | Esophagus | ESCC | 2.16e-30 | 5.88e-01 | 0.1666 |
| 8576 | STK16 | P36T-E | Human | Esophagus | ESCC | 1.02e-06 | 2.71e-01 | 0.1187 |
| 8576 | STK16 | P37T-E | Human | Esophagus | ESCC | 2.76e-13 | 2.32e-01 | 0.1371 |
| 8576 | STK16 | P38T-E | Human | Esophagus | ESCC | 6.68e-04 | 2.07e-01 | 0.127 |
| 8576 | STK16 | P39T-E | Human | Esophagus | ESCC | 7.95e-07 | 1.38e-01 | 0.0894 |
| 8576 | STK16 | P40T-E | Human | Esophagus | ESCC | 8.38e-14 | 2.33e-01 | 0.109 |
| 8576 | STK16 | P42T-E | Human | Esophagus | ESCC | 7.63e-10 | 2.65e-01 | 0.1175 |
| 8576 | STK16 | P44T-E | Human | Esophagus | ESCC | 1.94e-09 | 2.96e-01 | 0.1096 |
| 8576 | STK16 | P47T-E | Human | Esophagus | ESCC | 1.22e-09 | 2.13e-01 | 0.1067 |
| 8576 | STK16 | P48T-E | Human | Esophagus | ESCC | 5.87e-10 | 2.04e-01 | 0.0959 |
| 8576 | STK16 | P49T-E | Human | Esophagus | ESCC | 6.10e-16 | 1.32e+00 | 0.1768 |
| 8576 | STK16 | P52T-E | Human | Esophagus | ESCC | 7.21e-13 | 2.90e-01 | 0.1555 |
| 8576 | STK16 | P54T-E | Human | Esophagus | ESCC | 1.83e-15 | 3.44e-01 | 0.0975 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00715599 | Esophagus | ESCC | response to transforming growth factor beta | 157/8552 | 256/18723 | 2.95e-07 | 4.23e-06 | 157 |
| GO:00715609 | Esophagus | ESCC | cellular response to transforming growth factor beta stimulus | 151/8552 | 250/18723 | 1.78e-06 | 2.10e-05 | 151 |
| GO:004677710 | Esophagus | ESCC | protein autophosphorylation | 138/8552 | 227/18723 | 2.98e-06 | 3.38e-05 | 138 |
| GO:00182124 | Esophagus | ESCC | peptidyl-tyrosine modification | 202/8552 | 378/18723 | 1.34e-03 | 6.39e-03 | 202 |
| GO:00181084 | Esophagus | ESCC | peptidyl-tyrosine phosphorylation | 200/8552 | 375/18723 | 1.60e-03 | 7.45e-03 | 200 |
| GO:007155911 | Liver | Cirrhotic | response to transforming growth factor beta | 96/4634 | 256/18723 | 3.55e-06 | 6.09e-05 | 96 |
| GO:007156011 | Liver | Cirrhotic | cellular response to transforming growth factor beta stimulus | 93/4634 | 250/18723 | 7.34e-06 | 1.13e-04 | 93 |
| GO:007155921 | Liver | HCC | response to transforming growth factor beta | 141/7958 | 256/18723 | 3.08e-05 | 3.16e-04 | 141 |
| GO:007156021 | Liver | HCC | cellular response to transforming growth factor beta stimulus | 137/7958 | 250/18723 | 5.47e-05 | 5.14e-04 | 137 |
| GO:00467775 | Liver | HCC | protein autophosphorylation | 123/7958 | 227/18723 | 2.40e-04 | 1.80e-03 | 123 |
| GO:00715598 | Oral cavity | OSCC | response to transforming growth factor beta | 140/7305 | 256/18723 | 2.34e-07 | 3.70e-06 | 140 |
| GO:00715608 | Oral cavity | OSCC | cellular response to transforming growth factor beta stimulus | 137/7305 | 250/18723 | 2.68e-07 | 4.15e-06 | 137 |
| GO:00467779 | Oral cavity | OSCC | protein autophosphorylation | 123/7305 | 227/18723 | 2.31e-06 | 2.93e-05 | 123 |
| GO:00182123 | Oral cavity | OSCC | peptidyl-tyrosine modification | 180/7305 | 378/18723 | 3.63e-04 | 2.22e-03 | 180 |
| GO:00181083 | Oral cavity | OSCC | peptidyl-tyrosine phosphorylation | 177/7305 | 375/18723 | 6.86e-04 | 3.83e-03 | 177 |
| GO:007155917 | Skin | cSCC | response to transforming growth factor beta | 95/4864 | 256/18723 | 5.21e-05 | 5.31e-04 | 95 |
| GO:007156025 | Skin | cSCC | cellular response to transforming growth factor beta stimulus | 92/4864 | 250/18723 | 9.65e-05 | 8.99e-04 | 92 |
| GO:004677715 | Skin | cSCC | protein autophosphorylation | 84/4864 | 227/18723 | 1.53e-04 | 1.35e-03 | 84 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| STK16 | SNV | Missense_Mutation | rs371450121 | c.418N>A | p.His140Asn | p.H140N | O75716 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| STK16 | SNV | Missense_Mutation | c.313A>G | p.Thr105Ala | p.T105A | O75716 | protein_coding | deleterious(0.01) | possibly_damaging(0.484) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| STK16 | insertion | Frame_Shift_Ins | novel | c.267_268insACCTCAAAGATTTCTATATCTCTGCTCCTGAGGAGCTCACG | p.Ala90ThrfsTer35 | p.A90Tfs*35 | O75716 | protein_coding | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | SD | |||
| STK16 | insertion | Frame_Shift_Ins | novel | c.280_281insCCACTCAC | p.Trp95ThrfsTer19 | p.W95Tfs*19 | O75716 | protein_coding | TCGA-BH-A0BJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| STK16 | SNV | Missense_Mutation | c.701N>T | p.Pro234Leu | p.P234L | O75716 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD | |
| STK16 | SNV | Missense_Mutation | novel | c.158G>T | p.Cys53Phe | p.C53F | O75716 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EK-A2RL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | taxol | PD |
| STK16 | SNV | Missense_Mutation | novel | c.277G>A | p.Glu93Lys | p.E93K | O75716 | protein_coding | tolerated(0.08) | probably_damaging(0.999) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| STK16 | SNV | Missense_Mutation | c.112N>C | p.Glu38Gln | p.E38Q | O75716 | protein_coding | deleterious(0.02) | probably_damaging(0.988) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| STK16 | SNV | Missense_Mutation | novel | c.827A>G | p.Asp276Gly | p.D276G | O75716 | protein_coding | deleterious(0.01) | benign(0.318) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| STK16 | SNV | Missense_Mutation | rs548466076 | c.149N>A | p.Arg50Gln | p.R50Q | O75716 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 8576 | STK16 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME | inhibitor | 249565890 | ||
| 8576 | STK16 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
| 8576 | STK16 | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, ENZYME | inhibitor | 348353651 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |